Literature DB >> 29460229

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients.

Morgan Hakki1, James S Lewis2.   

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

Entities:  

Keywords:  Ceftolozane-tazobactam; Hematologic malignancy; Hematopoietic-cell transplant; Pseudomonas aeruginosa

Mesh：

Substances：

Year:  2018        PMID： 29460229     DOI： 10.1007/s15010-018-1125-5

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


  19 in total

1.  Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies.

Authors:  Enrico Maria Trecarichi; Mario Tumbarello; Morena Caira; Anna Candoni; Chiara Cattaneo; Domenico Pastore; Rosa Fanci; Annamaria Nosari; Nicola Vianelli; Alessandro Busca; Antonio Spadea; Livio Pagano
Journal:  Haematologica       Date:  2011-01       Impact factor: 9.941

2.  Emergence of Ceftolozane-Tazobactam-Resistant Pseudomonas aeruginosa during Treatment Is Mediated by a Single AmpC Structural Mutation.

Authors:  Shawn H MacVane; Ruchi Pandey; Lisa L Steed; Barry N Kreiswirth; Liang Chen
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

3.  P. aeruginosa bloodstream infections among hematological patients: an old or new question?

Authors:  Chiara Cattaneo; F Antoniazzi; S Casari; G Ravizzola; M Gelmi; C Pagani; M D'Adda; E Morello; A Re; E Borlenghi; N Manca; G Rossi
Journal:  Ann Hematol       Date:  2012-02-15       Impact factor: 3.673

Review 4.  Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant Enterococcus: Three major threats to hematopoietic stem cell transplant recipients.

Authors:  Michael J Satlin; Thomas J Walsh
Journal:  Transpl Infect Dis       Date:  2017-10-25       Impact factor: 2.228

5.  Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients.

Authors:  M Mikulska; V Del Bono; P Bruzzi; A M Raiola; F Gualandi; M T Van Lint; A Bacigalupo; C Viscoli
Journal:  Infection       Date:  2011-12-21       Impact factor: 3.553

6.  Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).

Authors:  Michael A Pfaller; Matteo Bassetti; Leonard R Duncan; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

7.  Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation.

Authors:  Désirée Caselli; Simone Cesaro; Ottavio Ziino; Giulio Zanazzo; Rosaria Manicone; Susanna Livadiotti; Monica Cellini; Stefano Frenos; Giuseppe M Milano; Barbara Cappelli; Maria Licciardello; Chiara Beretta; Maurizio Aricò; Elio Castagnola
Journal:  Haematologica       Date:  2010-03-19       Impact factor: 9.941

8.  Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance.

Authors:  Malgorzata Mikulska; Valerio Del Bono; Anna Maria Raiola; Barbara Bruno; Francesca Gualandi; Domenico Occhini; Carmen di Grazia; Francesco Frassoni; Andrea Bacigalupo; Claudio Viscoli
Journal:  Biol Blood Marrow Transplant       Date:  2009-01       Impact factor: 5.742

9.  Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).

Authors:  Helio S Sader; David J Farrell; Mariana Castanheira; Robert K Flamm; Ronald N Jones
Journal:  J Antimicrob Chemother       Date:  2014-06-10       Impact factor: 5.790

10.  Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Authors:  Alan J Xiao; Benjamin W Miller; Jennifer A Huntington; David P Nicolau
Journal:  J Clin Pharmacol       Date:  2015-08-25       Impact factor: 3.126
View more
  13 in total

1.  A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection.

Authors:  Ana Fernández-Cruz; Natalia Alba; María Auxiliadora Semiglia-Chong; Belén Padilla; Gabriela Rodríguez-Macías; Mi Kwon; Emilia Cercenado; Esther Chamorro-de-Vega; Marina Machado; Laura Pérez-Lago; Darío García de Viedma; José Luis Díez Martín; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

2.  Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections.

Authors:  Sarah C J Jorgensen; Trang D Trinh; Evan J Zasowski; Abdalhamid M Lagnf; Samuel P Simon; Sahil Bhatia; Sarah M Melvin; Molly E Steed; Natalie A Finch; Taylor Morrisette; Sandy J Estrada; Joshua R Rosenberg; Susan L Davis; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

Review 3.  Ceftazidime/Avibactam and Ceftolozane/Tazobactam for Multidrug-Resistant Gram Negatives in Patients with Hematological Malignancies: Current Experiences.

Authors:  Marianna Criscuolo; Enrico Maria Trecarichi
Journal:  Antibiotics (Basel)       Date:  2020-02-03

Review 4.  Understanding and Managing Sepsis in Patients With Cancer in the Era of Antimicrobial Resistance.

Authors:  Carlota Gudiol; Adaia Albasanz-Puig; Guillermo Cuervo; Jordi Carratalà
Journal:  Front Med (Lausanne)       Date:  2021-03-31

5.  A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Delaney E Hart; Jason C Gallagher; Laura A Puzniak; Elizabeth B Hirsch
Journal:  Open Forum Infect Dis       Date:  2021-03-06       Impact factor: 3.835

6.  Real-world use of ceftolozane/tazobactam: a systematic literature review.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Antimicrob Resist Infect Control       Date:  2021-04-08       Impact factor: 4.887

Review 7.  Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections.

Authors:  Laura Puzniak; Ryan Dillon; Thomas Palmer; Hannah Collings; Ashley Enstone
Journal:  Infect Dis Ther       Date:  2021-07-18

8.  Multicentre study of the in vitro activity of ceftolozane/tazobactam and other commonly used antibiotics against Pseudomonas aeruginosa isolates from patients in the UK.

Authors:  Adela Alvarez-Buylla; Mike Allen; Dan Betts; Sean Bennett; Irene Monahan; Tim Planche
Journal:  JAC Antimicrob Resist       Date:  2020-05-30

Review 9.  Ceftolozane/Tazobactam for Resistant Drugs Pseudomonas aeruginosa Respiratory Infections: A Systematic Literature Review of the Real-World Evidence.

Authors:  Luca Gregorio Giaccari; Maria Caterina Pace; Maria Beatrice Passavanti; Francesca Gargano; Caterina Aurilio; Pasquale Sansone
Journal:  Life (Basel)       Date:  2021-05-24

10.  An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients.

Authors:  Milo Gatti; Bruno Viaggi; Gian Maria Rossolini; Federico Pea; Pierluigi Viale
Journal:  Antibiotics (Basel)       Date:  2021-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.